Knight Therapeutics, Inc. (GUD.TO)
10.25
+0.02
(+0.20%)
CAD |
TSX |
Sep 18, 16:00
Knight Therapeutics Enterprise Value : 931.47M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 931.47M |
| September 17, 2026 | 929.50M |
| September 16, 2026 | 907.89M |
| September 15, 2026 | 902.98M |
| September 14, 2026 | 908.88M |
| September 11, 2026 | 892.18M |
| September 10, 2026 | 880.39M |
| September 09, 2026 | 897.09M |
| September 08, 2026 | 897.09M |
| September 04, 2026 | 907.89M |
| September 03, 2026 | 910.84M |
| September 02, 2026 | 874.50M |
| September 01, 2026 | 871.55M |
| August 31, 2026 | 873.52M |
| August 28, 2026 | 854.85M |
| August 27, 2026 | 866.64M |
| August 26, 2026 | 883.34M |
| August 25, 2026 | 882.36M |
| August 24, 2026 | 873.52M |
| August 21, 2026 | 873.52M |
| August 20, 2026 | 870.57M |
| August 19, 2026 | 889.23M |
| August 18, 2026 | 880.39M |
| August 17, 2026 | 885.30M |
| August 14, 2026 | 840.12M |
| Date | Value |
|---|---|
| August 13, 2026 | 829.32M |
| August 12, 2026 | 837.17M |
| August 11, 2026 | 857.80M |
| August 10, 2026 | 839.14M |
| August 07, 2026 | 883.34M |
| August 06, 2026 | 857.80M |
| August 05, 2026 | 834.23M |
| August 04, 2026 | 842.08M |
| July 31, 2026 | 891.20M |
| July 30, 2026 | 884.32M |
| July 29, 2026 | 894.14M |
| July 28, 2026 | 891.20M |
| July 27, 2026 | 889.23M |
| July 24, 2026 | 880.39M |
| July 23, 2026 | 876.46M |
| July 21, 2026 | 903.97M |
| July 20, 2026 | 891.20M |
| July 17, 2026 | 889.23M |
| July 16, 2026 | 876.46M |
| July 15, 2026 | 879.41M |
| July 14, 2026 | 887.27M |
| July 13, 2026 | 887.27M |
| July 10, 2026 | 887.27M |
| July 09, 2026 | 913.79M |
| July 08, 2026 | 906.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 162.24M |
| Bausch Health Cos., Inc. | 31.21B |
| Cipher Pharmaceuticals, Inc. | 360.43M |
| BioSyent, Inc. | 172.58M |
| Revive Therapeutics Ltd. | 8.762M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.361M |
| Revenue (Quarterly) | 144.21M |
| Total Expenses (Quarterly) | 147.57M |
| EPS Diluted (Quarterly) | -0.0342 |
| Gross Profit Margin (Quarterly) | 38.94% |
| Profit Margin (Quarterly) | -2.33% |
| Earnings Yield | 1.47% |
| Operating Earnings Yield | 2.60% |
| Normalized Earnings Yield | 1.977 |